The patient was a 15-year-old girl with severe acute hepatitis. A liver biopsy showed the typical findings of autoimmune hepatitis (AIH). Subsequently, two lineages of cytopenia were found in the patient's peripheral blood. Hemophagocytosis by macrophages was observed in the bone marrow. Virus-, drug-and lymphoma-associated hemophagocytic syndrome (HPS) was ruled out. Therefore, the patient was diagnosed with autoimmune-associated HPS (AAHS). Following the administration of combination therapy with prednisolone and cyclosporine A, both the AAHS and AIH improved. This is the first report of AAHS originating from AIH. The patient was followed up for five years after treatment, and no disease recurrence was detected.
Introduction
Hemophagocytic syndrome (HPS) is a clinicopathological entity characterized by a high-grade fever, hepatosplenomegaly, cytopenia, a high ferritin level and increased proliferation and activation of benign macrophages with hemophagocytosis in the bone marrow or other reticuloendothelial systems (1) . HPS is classified as genetic (primary) or acquired (secondary). Primary HPS includes familial hemophagocytic lymphohistiocytosis, X-linked lymphoproliferative syndrome, Chediak-Higashi syndrome and Griscelli syndrome (2) . Secondary HPS includes infectionassociated HPS (IAHS), malignancy-associated HPS, autoimmune-associated HPS (AAHS) and drug-associated HPS (3) (4) (5) (6) (7) (8) (9) .
AAHS is frequently observed in patients with systemic lupus erythematosus (SLE) or adult-onset Still's disease (AOSD). Its prevalence has been found to be 4.6% in SLE patients and 7.7% in AOSD patients (10) . On the other hand, AAHS is rarely observed in patients with juvenile idiopathic arthritis or multicentric Castleman's disease (11) and has not been reported in patients with autoimmune hepatitis (AIH). Almost all cases of HPS in patients with systemic autoimmune diseases other than SLE or AOSD have been shown to be complicated by infectious events or malignancy (5). This paper is the first to report a case of AAHS originating from AIH that was not complicated by infection or malignancy. Moreover, the patient was followed up for a long period after treatment. 
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tory of medication use, including health food supplements or blood transfusions. On an examination performed at a local hospital on the beginning of January (day 0), 2008, her bulbar conjunctiva was icteric, and blood tests showed liver dysfunction, as follows: total bilirubin (T-Bil), 9.9 mg/dL; aspartate aminotransferase (AST), 867 IU/L; alanine aminotransferase (ALT), 1,774 IU/l; and prothrombin time (PT), 69%. Therefore, she was admitted to our hospital for a further evaluation.
At admission on day 7, the patient's consciousness was clear, and her body temperature was 37. (-) . Based on these findings, the patient was diagnosed with acute hepatic failure without coma. Abdominal ultrasonography and a CT scan showed hepatosplenomegaly (Fig. 1) ; however, they did not demonstrate either dilatation of the common bile or intrahepatic bile ducts, indicating no obstructive jaundice. The images also did not reveal fatty liver. The patient was maintained under conditions of complete bed rest and received a drip infusion of glucose and coagulation factor.
A fine needle aspiration biopsy of the liver parenchyma was performed; the specimen exhibited typical AIH findings, such as interface hepatitis and histiocytic and lymphocytic infiltrates in the portal tracts extending into the lobule with hepatic rosette formation (Fig. 2) . Together with the simplified diagnostic criteria for AIH described by Hennes et al. (12) , the patient had a total of 6 points, suggesting probable AIH. On day 22, a blood test showed cytopenia of he- 
moglobin (8.3 g/dL) and platelets (7.3×10 4 /μL). A bone marrow test was performed, and hemophagocytosis by macrophages and normoblastic marrow were observed (Fig. 3) . On day 24, combination therapy consisting of prednisolone (50 mg/day) and cyclosporine A (100 mg/day) was initiated ( Fig. 4) .
On day 103, the levels of hemoglobin and platelets had improved (12.6 g/dL and 20.4×10 4 /μL, respectively). A bone marrow test was performed again, and no hemophagocytosis was detected. The levels of T-Bil, AST and ALT had also improved (1.1 mg/dL, 13 IU/L and 20 IU/L, respectively). In addition, the IgG titer had declined to 424 mg/dL. A liver biopsy was performed again, and no significant findings of AIH were observed (Fig. 5) . Subsequently, the doses of prednisolone and cyclosporine A were gradually tapered due to the lack of recurrence of either AIH or AAHS. In January 2013 (five years after the development of AIH and AAHS), the patient finally stopped taking any medications.
Discussion
Many autoimmune disorders causative of AAHS have been reported. In 1991, Wong et al. reported patients with active SLE who demonstrated reactive HPS in the bone marrow (10) . The occurrence of HPS was associated with the activity of SLE itself, and the authors proposed the disease entity of acute lupus HPS. In 1995, Kumakura et al. reported patients with reactive HPS associated with autoimmune diseases other than SLE and first proposed the disease entity of AAHS with diagnostic criteria (3) . In this paper, we are the first to report a patient with AAHS originating from acute-onset AIH. The clinical features of acute-onset AIH include a higher serum ALT level, a lower serum IgG level and a lower AIH score in comparison with those observed in patients with classical AIH, as previously described (13) .
The diagnosis of AAHS requires the presence of cytopenia affecting at least two lineages in the peripheral blood and the pathological finding of histiocytic hemophagocytosis in the bone marrow (8) . Our patient exhibited two lineages of cytopenia (hemoglobin and platelets) in the peripheral blood and hemophagocytosis by macrophages in the bone marrow. In addition to these two factors, the diagnosis of AAHS requires confirmation that HPS occurs in the active phase of the underlying autoimmune disease, since the occurrence of AAHS is usually dependent on the disease activity (8) . Our patient presented with severe acute hepatitis and subsequently developed HPS; therefore, the close correlation between the disease activity and the extent of HPS supports the possibility of AAHS. It is also necessary to ex- 
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clude other types of reactive HPS, such as virus-, drug-or lymphoma-associated HPS (8) . In this case, no clinical manifestations of active viral infection were detected. The HPS developed before the administration of immunosuppressive therapy. Moreover, a successful response to therapy was obtained, indicating the unlikeliness of underlying infectious disease. Incompatible blood infusions and drugs, including health food supplements, are sometimes associated with the development of HPS; however, such treatments were not administered in this case. The patient also had no evidence of underlying lymphoma or other known disorders causative of reactive HPS. All of the four criteria for a diagnosis of AAHS were fulfilled in the present case. Therefore, a diagnosis of AAHS was made.
The present patient did not exhibit a high fever or high levels of LDH or C-reactive protein (CRP). These findings are not always found in AAHS patients. Patients without these findings have been reported to have various autoantibodies against hematopoietic cells (8) . Our patient was positive for ANA. Autoantibodies directed against hematopoietic cells are produced and bind to specific hematopoietic cells. The sensitized hematopoietic cells are recognized and phagocytosed by histiocytes via binding of the Fc portion of the antibodies and the Fc receptor on histiocytes (3, 4) . On the other hand, patients with these findings have been reported to have elevated levels of serum cytokines, such as interleukin (IL)-1β, IL-16 and macrophage-colony stimulating factor (M-CSF), without the presence of autoantibodies against hematopoietic cells (8) . Although we were unable to examine the expression levels of these serum cytokines in the present case, it is thought that the differences in clinical features depend on the mechanism underlying hemophagocytosis.
The treatment of AAHS is indicated in patients suffering from the active phase of the disease who exhibit severe cytopenia or progression of cytopenia. The treatment consists of therapy for the underlying disease. No standard treatment for AAHS has been established; however, most AAHS patients respond to immunosuppressive agents, such as corticosteroids. In severe cases or patients refractory to high-dose corticosteroid therapy, methylprednisolone pulse treatment is sometimes needed (8) . In addition, a favorable effect of etoposide was reported in the treatment of a severe and refractory case of AAHS (14) . Treatment with granulocytecolony stimulating factor (G-CSF) is a reliable alternative, which increases the neutrophil count in the majority of patients with neutropenia. The administration of G-CSF is beneficial in some AAHS patients with severe or lifethreatening neutropenia. Other therapies include cyclosporine A, high-dose intravenous immunoglobulin G, plasma exchange and cytotoxic agents (15, 16) . Our patient demonstrated severe anemia and thrombopenia in addition to life-threatening underlying disease; therefore, she was treated with both prednisolone and cyclosporine A. A successful response was obtained following the administration of these drugs, and no disease recurrence was detected five years after treatment.
In conclusion, this is the first report of a case of AAHS originating from AIH with a successful response to therapy. The patient was followed up for a long period after treatment, and no disease recurrence was detected.
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